Pharvaris Investor Relations Material

Pharvaris N.V. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare diseases, particularly hereditary angioedema (HAE). The company specializes in creating oral bradykinin B2 receptor antagonists, offering alternatives to existing injected treatments. Its key developments include PHVS416, a soft capsule for on-demand use during acute HAE attacks, and PHVS719, an extended-release tablet aimed at preventing such attacks. Pharvaris operates primarily in the Netherlands, Switzerland, and the United States. The company is headquartered in Leiden, the Netherlands, and its shares are listed on the NASDAQ.